Atea Pharmaceuticals Inc. (AVIR)
$4.10
$-0.17
(-3.98%)
As on 15-May-2026 16:00EDT
Market cap
$433 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-260.5
-
Debt to Equity
0
-
Book Value
$3.4
-
EPS
$-2
-
Face value
--
-
Shares outstanding
80,027,099
6 Years Aggregate
CFO
$-17.37 Mln
EBITDA
$-190.79 Mln
Net Profit
$-164.06 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
| 14.8 | -29.3 | -4.9 | 60.8 | 8.1 | -29.1 | -- |
|
BSE Sensex
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
| 6.6 | 9.8 | -36.6 | -46.2 | -78.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
4.1 | 433.0 | 0.0 | -158.4 | -- | -44.3 | -- | 1.6 |
| 76.7 | 10,950.2 | 622.0 | -300.9 | -7.4 | -62.9 | -- | 16.7 | |
| 75.9 | 10,123.1 | 105.8 | -829.6 | -718.2 | -- | -- | 60.3 | |
| 50.1 | 12,494.9 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.5 | 6.3 | |
| 94.9 | 12,823.7 | 1,080.2 | -433.2 | -29.6 | -- | -- | 55.7 | |
| 8.0 | 8,494.0 | 141.0 | -854.5 | -97.9 | -- | -- | 0.0 | |
| 306.3 | 9,223.6 | 417.3 | 225.0 | 42.8 | 18.6 | 41.8 | 7.1 | |
| 523.7 | 11,459.4 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 21.6 | |
| 415.3 | 11,917.7 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.2 | 20.2 | |
| 342.6 | 9,250.5 | 0.0 | -326.5 | -- | -37.2 | -- | 6.5 |
Shareholding Pattern
View DetailsAbout Atea Pharmaceuticals (AVIR)
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a... nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Address: 225 Franklin Street, Boston, MA, United States, 02110 Read more
-
Founder, Chairman, CEO & President
Dr. Jean-Pierre Sommadossi Ph.D.
-
Founder, Chairman, CEO & President
Dr. Jean-Pierre Sommadossi Ph.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Atea Pharmaceuticals (AVIR)
What is the current share price of Atea Pharmaceuticals Inc (AVIR) Today?
The share price of Atea Pharmaceuticals Inc (AVIR) is $4.10 (NASDAQ) as of 15-May-2026 16:00 EDT. Atea Pharmaceuticals Inc (AVIR) has given a return of 8.05% in the last 3 years.
What is the current PB & PE ratio of Atea Pharmaceuticals Inc (AVIR)?
Since, TTM earnings of Atea Pharmaceuticals Inc (AVIR) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.83
|
1.05
|
|
2024
|
-1.67
|
0.64
|
|
2023
|
-1.86
|
0.46
|
|
2022
|
-3.44
|
0.62
|
|
2021
|
6.49
|
1.11
|
What is the 52 Week High and Low of Atea Pharmaceuticals Inc (AVIR)?
The 52-week high and low of Atea Pharmaceuticals Inc (AVIR) are Rs 6.45 and Rs 2.46 as of 17-May-2026.
What is the market cap of Atea Pharmaceuticals Inc (AVIR)?
Atea Pharmaceuticals Inc (AVIR) has a market capitalisation of $ 433 Mln as on 12-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Atea Pharmaceuticals Inc (AVIR)?
Before investing in Atea Pharmaceuticals Inc (AVIR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.